Thrombotic microangiopathy and digital necrosis: Two unrecognized toxicities of gemcitabine

Anti-Cancer Drugs

Volumn 14, Issue 10, 2003, Pages 829-832

  Venat Bouvet L ^a   Ly, K ^a   Szelag, J C ^a   Martin, J ^a   Labourey, J L ^a   Genet, D ^a   Tubiana Mathieu, N ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

Digital necrosis; Gemcitabine; Hemolytic uremic syndrome; Thrombotic microangiopathy

Indexed keywords

GEMCITABINE; ILOPROST;

ACUTE KIDNEY FAILURE; ADENOCARCINOMA; ADULT; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FINGER NECROSIS; FINGER TIP INJURY; HEMOLYTIC UREMIC SYNDROME; HUMAN; MALE; PANCREAS CARCINOMA; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADENOCARCINOMA; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; FINGERS; GANGRENE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; ILOPROST; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; URINARY BLADDER NEOPLASMS; VASODILATOR AGENTS;

EID: 17744407601     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Green MR. Gemcitabine safety overview. Semin Oncol 1996; 23(suppl 10):S32-S35.
2. Flombaum CD, Mouradian JA, Casper ES, Erlandson RA, Benedetti F. Thrombotic microangiopathy as a complication of long term therapy with gemcitabine. Am J Kidney Dis 1999; 33:555-562.
3. Lhotta K, Kuhr T, Rumpelt HJ, Woll E, Thaler J, Konig P. Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy. Am J Nephrol 1999; 19:590-593.
4. Dilhuydy MS, Delclaux C, Pariente A, De Precigout V, Aparicio M. Syndrome hémolytique et urémique compliquant un traitement au long cours par gemcitabine. A propos d'un cas, revue de la littérature. Rev Med Interne 2002; 23:189-192.
5. Teixeira L, Debourdeau P, Zammit C, Estival JL, Pavic M, Colle B. Thrombotic microangiopathy due à la gemcitabine. Presse Med 2002; 31:740-742.
6. Banach MJ, Williams GA. Purtscher retinopathy and necrotizing vasculitis with gemcitabine therapy. Arch Opthalmol 2000; 118:726-727.
7. Voorburg AMCJ, van Beek FT, Slee PHThJ, Seldenrijk CA, Schramel FMNH. Vasculitis due to gemcitabine. Lung Cancer 2002; 36:203-205.
8. Moake JL, Haemolytic uraemic syndrome: basic science. Lancet 1994; 343:393-397.
9. Lorhman HP, Adam W, Heymer B, Kubanek B. Microangiopathic haemolytic anemia in metastatic carcinoma: report of eight cases. Ann Intern Med 1973; 79:368-375.
10. Murgo A. Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents. Semin Hematol 1987; 24:161-177.
11. Schiebe ME, Hoffmann W, Belka C, Bamberg M. Mitomycine C-related hemolytic syndrome in cancer patients. Anticancer Drugs 1998; 9:433-435.
12. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non small cell cancer: a phase II study. J Clin Oncol 1994; 12:1535-1540.
13. Ahmed I, Chen KR, Nakayama H, Gibson LE. Cytosine arabinoside-induced vasculitis. Mayo Clinic Proc 1998; 73:239-242.
14. Claudy A. Pathogenesis of leucocytoclastic vasculitis. Eur J Dermatol 1998; 8:75-79.
15. Marruchella A, Fiorenzano G, Merizzi A, Rossi G, Chiodera PL. Diffuse alveolar damage in a patient treated with gemcitabine. Eur Respir J 1998; 11:504-506.
16. Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997; 80:286-291.
17. Sullivan TP, King LE, Boyd AS. Colchicine in dermatology. J Am Acad Dermatolol 1998; 39:993-999.
18. Gallen JP, Ekenstam FE. Cutaneous leucocytoclastic vasculitis: clinical experience in 44 patients. South Med J 1987; 80:848-851.